Effects of a standardized Ayurvedic formulation on diabetes control in newly diagnosed Type-2 diabetics; a randomized active controlled clinical study

Complementary Therapies in Medicine

Volumn 23, Issue 4, 2015, Pages 555-561

  Awasthi, Harshika ^a   Nath, Rajendra ^a   Usman, Kauser ^a   Mani, Dayanandan ^b   Khattri, Sanjay ^a   Nischal, Anuradha ^a   Singh, Manju ^b   Sawlani, Kamal Kumar ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

Clinical research; Herbal remedies; Polyherbal formulation; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AYURVEDIC DRUG; BERBERINE; BERBERIS ARISTATA EXTRACT; CEDRUS DEODARA EXTRACT; CHOLESTEROL; CYPERUS ROTUNDUS EXTRACT; EMBLICA OFFICINALIS EXTRACT; GALLIC ACID; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; QUERCETIN; TERMINALIA BELLIRICA EXTRACT; TERMINALIA CHEBULA EXTRACT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PLANT EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; LIPID HOMEOSTASIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; AYURVEDA; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICINE, AYURVEDIC; METFORMIN; MIDDLE AGED; PLANT EXTRACTS;

EID: 84939183431     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2015.06.005     Document Type: Article

References (31)

1. Kahn S.E., Cooper M.E., Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2013, 383(9922):1068-1083.
2. Diagnosis and classification of diabetes mellitus. Diabetes Care, 37 (Suppl 1); 2014: S81-S90.
3. Tuomi T., Santoro N., Caprio S., Cai M., Weng J., Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014, 383(9922):1084-1094.
4. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383(9911):69-82.
5. Boutayeb A., Boutayeb S., Boutayeb W. Multi-morbidity of non communicable diseases and equity in WHO Eastern Mediterranean countries. Int J Equity In Health 2013, 12:60.
6. Chen Z.C., Zhang S.L., Yan L., Wu M.C., Chen L.H., Ji L.N. Association between side effects of oral anti-diabetic drugs and self-reported mental health and quality of life among patients with type 2 diabetes. Zhonghua Yi Xue Za Zhi 2011, 91(4):229-233.
7. Tikoo K., Misra S., Rao K.V., Tripathi P., Sharma S. Immunomodulatory role of an Ayurvedic formulation on imbalanced immunometabolics during inflammatory responses of obesity and prediabetic disease. Evid Based Complement Alternat Med 2013, 705072.
8. Ven Murthy M.R., Ranjekar P.K., Ramassamy C., Deshpande M. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: ashwagandha. Cent Nerv Syst Agents Med. Chem. 2010, 10(3):238-246.
9. Brar B.S., Norman R.G., Dasanayake A.P. Involvement of Ayurvedic practitioners in oral health care in the United States. J Am Dental Assoc 2012, 143(10):1120-1126.
10. Pompo G.D., Poli F., Mandrone M., Lorenzi B., Roncuzzi L., Baldini N., et al. Comparative in vitro evaluation of the antiresorptive activity residing in four Ayurvedic medicinal plants. Hemidesmus indicus emerges for its potential in the treatment of bone loss diseases. J Ethnopharmacol 2014, 154(2):462-470.
11. Rather M.A., Bhat B.A., Qurishi M.A. Multicomponent phytotherapeutic approach gaining momentum: Is the one drug to fit all model breaking down?. Phytomedicine 2013, 21(1):1-14.
12. Singh J., Kakkar P. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol 2009, 123(1):22-26.
13. Raut N.A., Gaikwad N.J. Antidiabetic activity of hydro-ethanolic extract of Cyperus rotundus in alloxan induced diabetes in rats. Fitoterapia 2006, 77(7-8):585-588.
14. Sabu M.C., Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002, 81(2):155-160.
15. Awasthi H., Mani D., Nath R., Kumar S. Anti-hyperglycaemic activity of a polyherbal formulation and its protective role against hepatopathy in streptozotocin induced diabetic rats. Int J Curr Res 2013, 5(10):3184-3191.
16. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. Faseb J 2008, 22(3):659-661.
17. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Int Med 2010, 152(11):726-732.
18. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care. 33 (Suppl. 1); 2010: S11-S61.
19. White S.J., Freedman L.S. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978, 37(5):849-857.
20. Monnier L., Colette C. Target for glycemic control: concentrating on glucose. Diabetes Care 2009, 32(Suppl 2):S199-S204.
21. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 37 Suppl 1; 2014: S14-80.
22. American Heart Association. Cholesterol Abnormalities & Diabetes 2013. Available from: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cholesterol-Abnormalities-Diabetes_UCM_313868_Article.jsp.
23. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55(8):2256-2264.
24. Wei W., Zhao H., Wang A., Sui M., Liang K., Deng H., et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 2012, 166(1):99-105.
25. Hardie D.G. AMPK a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013, 62(7):2164-2172.
26. Turner N., Li J.Y., Gosby A., To S.W., Cheng Z., Miyoshi H., et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57(5):1414-1418.
27. Jialal I., Amess W., Kaur M. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep 2010, 10(4):316-320.
28. Williams G., Pickup J.C. Handbook of Diabetes 2004, Wiley.
29. Dong H., Zhao Y., Zhao L., Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 2013, 79(6):437-446.
30. Xiao H.B., Sun Z.L., Zhang H.B., Zhang D.S. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep 2012, 64(4):889-895.
31. Hoek E.F., Keijer J., Bunschoten A., Vervoort J.J.M., Stankova B., Bekkenkamp M., et al. Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice. PLoS One 2013, 8(1):e51588.